In a bid to combat the ongoing Ebola outbreak, a groundbreaking trial of potential treatments for the virus has commenced in the Democratic Republic of Congo (DRC), as announced by the World Health Organization (WHO) on Thursday. The first patient was enrolled in the trial, which is being sponsored by the WHO and coordinated by scientists from the Institut National de Recherche Biomédicale in DRC, the Institute of Tropical Medicine in Belgium, and the University of Oxford in the United Kingdom. The trial aims to test two therapeutics against the Bundibugyo virus strain, which has caused over 1,400 confirmed cases and 438 deaths in the DRC alone since May, as per WHO data up until June 30th. The outbreak has also spread to Uganda, with 20 confirmed cases leading to two fatalities, and one case reported in France. Ebola is a highly infectious disease that primarily affects animals but can sometimes spread to humans through contact with infected creatures. Symptoms, which include fever, headache, and tiredness, usually appear two to 21 days after exposure and resemble those of flu or malaria. As the virus attacks the immune system and organs, no approved vaccines or treatments currently exist for this particular strain. The WHO emphasizes that while some patients are recovering without approved therapeutics, effective treatments could significantly reduce mortality rates, saving many more lives during outbreaks. The current crisis has been declared a public health emergency by the WHO, underscoring the urgent need for innovative solutions to curb the spread of Ebola and protect global health.